This systematic review investigated dual strategies targeting angiogenesis for the treatment of systemic osteoporosis and the enhancement of osteoporotic fracture healing. The scope included mesenchymal stem cells and their exosomes, phytochemicals, traditional Chinese medicine compounds, non-coding RNAs, proteins or peptides, repurposed clinical drugs, and non-invasive physical therapies. However, the study population, sample size, setting, and follow-up duration were not reported in the available data.
The review noted that primary and secondary outcomes, as well as specific main results with numerical data, were not reported. Consequently, no quantitative efficacy data could be extracted from this evidence base. Safety profiles regarding adverse events, serious adverse events, discontinuations, and overall tolerability were also not reported for the interventions under consideration.
Key limitations highlighted include issues with target specificity, translational barriers, and a distinct lack of robust clinical evidence. Because the study phase was not reported and funding or conflicts of interest were not disclosed, the certainty of any potential benefit remains uncertain. The practice relevance of these findings is currently unclear given the incomplete nature of the evidence.
In summary, while angiogenesis-targeting strategies are of theoretical interest, this review provides no definitive clinical guidance. The absence of reported data on who was studied, what specific outcomes were measured, and how well these therapies were tolerated precludes immediate clinical application.
View Original Abstract ↓
Osteoporosis (OP) and its related fragility fractures represent a significant global health burden, primarily characterized by reduced bone mass, deteriorated microarchitecture, and compromised self-repair capacity. While current mainstream therapies focusing on anti-resorption and anabolic pathways can slow bone loss, they often fall short in reversing established skeletal deficits and, particularly, in facilitating fracture healing. Growing evidence underscores that angiogenesis is fundamentally coupled with osteogenesis, forming the cornerstone of bone homeostasis and injury repair. However, developing therapeutic strategies targeting this “vascular-bone” axis remains a relatively nascent and underexplored area in the clinical management of both systemic osteoporosis and osteoporotic fractures. This review aims to provide a comprehensive synthesis of dual strategies targeting angiogenesis for the treatment of systemic osteoporosis and the enhancement of osteoporotic fracture healing. We first analyze the pivotal role and regulatory networks of angiogenesis in maintaining bone homeostasis and within the fracture repair microenvironment. Subsequently, we systematically categorize and critically evaluate various intervention strategies based on this approach, including mesenchymal stem cells and their exosomes with paracrine functions, phytochemicals and traditional Chinese medicine compounds possessing dual regulatory activities, non-coding RNAs (miRNAs, lncRNAs, circRNAs) that modulate key signaling pathways, proteins or peptides with defined pro-angiogenic activity, repurposed clinical drugs with potential vascular-modulating properties, and non-invasive physical therapies. The article further compares and contrasts the application of these strategies for systemic bone mass restoration versus localized fracture repair, discussing differences in delivery methods, molecular targets, and expected outcomes. Finally, we address the current challenges in the field—such as target specificity, translational barriers, and the lack of robust clinical evidence—and outline future research directions. By integrating existing knowledge, this review seeks to provide a theoretical foundation and novel perspectives for developing next-generation, synergistic therapies centered on vascular regeneration, designed to concurrently improve bone mineral density and bone quality.